Insight

Aradhana Kasimsetty: Denise Sabatino and I present a review of the known risks of AAV vector-mediated liver cancer

Photo collage of Aradhana Kasimsetty and Denise Sabatino

Apr 21, 2024, 18:27

Aradhana Kasimsetty: Denise Sabatino and I present a review of the known risks of AAV vector-mediated liver cancer

Aradhana Kasimsetty, , shared on LinkedIn:

“With the recent FDA guidances on gene therapy products, risk management and concerns of vector-derived malignancies are at the forefront of clinical development.

As part of the special issue “Liver Directed Adeno‐Associated Virus Gene Therapy”, Denise Sabatino and I present a review of the known risks of AAV vector-mediated liver cancer and how integration site monitoring synergizes with routine patient care after liver-directed gene therapy.

Integration and the risk of liver cancer—Is there a real risk?”

Additional information.
Source: Aradhana Kasimsetty/LinkedIn

Adeno‐Associated Virus Gene Therapy Aradhana Kasimsetty cancer Denise Sabatino FDA gene therapy liver cancer OncoDaily Oncology Perelman School of Medicine

Mark Ruffalo and Brain Cancer: How He Went Against, How He Survived, and More

Sharon Osbourne and Colon Cancer: How She Went Against, How She Survived, and More

Marcia Cross and Anal Cancer: How She Went Against, How She Survived, and More

Pancreatic Cancer: Symptoms, Causes, Types, Diagnosis & Treatment

FDA approves Methotrexate for Pediatric acute Lymphoblastic Leukemia

Special Coverage